China Pharma Holdings, Inc. (CPHI)

CN — Healthcare Sector
Peers: UPC  SNOA  ACOR  AKAN  HCANF  ALIM  SXTC  PTPI  BFRI  GHSI  SHPH  GRCU  CNNA  RMRK  GXXY  INQD  MNK  LFCR  LSDI  ADMP 

Automate Your Wheel Strategy on CPHI

With Tiblio's Option Bot, you can configure your own wheel strategy including CPHI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CPHI
  • Rev/Share 348.3511
  • Book/Share 2136.7376
  • PB 0.0009
  • Debt/Equity 0.2027
  • CurrentRatio 0.5566
  • ROIC -0.0832

 

  • MktCap 6197800.0
  • FreeCF/Share -35.6068
  • PFCF -0.0001
  • PE -0.0079
  • Debt/Assets 0.0994
  • DivYield 0
  • ROE -0.4508

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 5
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About China Pharma Holdings, Inc. (CPHI)

  • IPO Date 2002-04-17
  • Website https://www.chinapharmaholdings.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Ms. Zhilin Li
  • Employees 224
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.